People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Pharmaceuticals, Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Curevo, Inc. | — | Pharmaceuticals | Series C | $110.0M | $293.0M | 2025 |
| Averna Therapeutics Inc. | — | Pharma | Series C | $85.0M | $805.0M | 2024 |
| Convergent Therapeutics, Inc. | — | Biotechnology | Series B | $51.4M | $152.9M | 2023 |
Tal Zaks at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tal Zaks on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Squinto | 1 | 8 |
| Dylan Morris | 1 | 8 |
| Henry Chen | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Jake Simson | 1 | 6 |
| Richard Morris | 1 | 4 |
| Mario Barro | 1 | 3 |
| Alexander Brown | 1 | 3 |
| Moncef Slaoui | 1 | 3 |
| Eric Sullivan | 1 | 3 |
| Giovanni Mariggi | 1 | 2 |
| Nick Olsen | 1 | 2 |
| Charles Petty | 1 | 2 |
| Julie Brooks | 1 | 1 |
| Jim Trenkle | 1 | 1 |
| Philip Kantoff | 1 | 1 |
| Neil Bander | 1 | 1 |
| Thomas Barnes | 1 | 1 |
| Roy Amariglio | 1 | 1 |
| Raju Prasad | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.